key: cord-0874716-k2oyzr2z authors: Kerry, Rout George; Malik, Santosh; Redda, Yisehak Tsegaye; Sahoo, Sabuj; Patra, Jayanta Kumar; Majhi, Sanatan title: Nano-based approach to combat emerging viral (NIPAH virus) infection date: 2019-03-21 journal: Nanomedicine DOI: 10.1016/j.nano.2019.03.004 sha: 2b32ff14b35f71ce148ca70e0d0669b10d642ae8 doc_id: 874716 cord_uid: k2oyzr2z Emergence of new virus and their heterogeneity are growing at an alarming rate. Sudden outburst of Nipah virus (NiV) has raised serious question about their instant management using conventional medication and diagnostic measures. A coherent strategy with versatility and comprehensive perspective to confront the rising distress could perhaps be effectuated by implementation of nanotechnology. But in concurrent to resourceful and precise execution of nano-based medication, there is an ultimate need of concrete understanding of the NIV pathogenesis. Moreover, to amplify the effectiveness of nano-based approach in a conquest against NiV, a list of developed nanosystem with antiviral activity is also a prerequisite. Therefore the present review provides a meticulous cognizance of cellular and molecular pathogenesis of NiV. Conventional as well several nano-based diagnosis experimentations against viruses have been discussed. Lastly, potential efficacy of different forms of nano-based systems as convenient means to shield mankind against NiV has also been introduced. In view of the adaptable nanotechnological achievements in the past decade, it is certain that, nanoscience is consistently intensifying its horizon across the globe in present and will be in centuries to come. Despite the expendability and plasticity in nanotechnological application, there is a wide gap in intrigue experimental biomedical application and their substantial commercialization. Moreover, their application in biomedical science is still lurking, and should be prioritized in order to bridge the gap. Additionally, the efficacy of conventional therapies is gradually fading away specifically in case of viral infections due to the development of resistance, 1 which could be certainly due to accelerated adaptation in peripheral protein sequence resulting in newfangled viral strain. Van Woensel et al for instance have stated that viruses are the ubiquitous causes of lower respiratory tract disease in babies and youngsters. Later a variation of coronavirus associated with severe acute respiratory syndrome and human metapneumovirus, lately recognized as a new respiratory pathogen over the entire age range has emerged. 2 And presently Nipah virus (NiV) another respiratory tract infecting virus with an estimated case fatality rate ranging from 40% to 75% is causing serious issue through the world. 3 As indicated by WHO fact-sheet report, lower respiratory infection is ranked 1st and 6th leading cause of mortalities in low income countries and high income countries, respectively, and 4th leading cause of mortalities worldwide. 4 The BSL-4 virus with this high rate of morbidity and mortality, up to some extent has strangled the virologist since past 10 years or so for the exigency for a novel therapeutics. 5 Moreover, the conventional unidirectional serological diagnosis and therapeutics orchestrate numeral shortcomings such as cost deficit, sophisticated preparation procedures, efficient only on postexposure prophylaxis and reduced amount of the product in consistent with human population and livestock to be vaccinated. 5, 6 Majority of the therapeutics developed basically includes monoclonal antibodies targeting viral surface proteins such as F, G or M proteins. [7] [8] [9] Further a number of broad spectrum antiviral agents such as nucleoside analogues namely rebavirin, GS-441524, GS-5734 (remdesivir), R1479 (balapiravir) and most recent drug favipiravir (T-705; 6-flouro-3-hydroxy-2-pyrazinecarboxamine) which is an inhibitor of viral RNA-dependent RNA polymerase have shown certain degree of efficiency against this virus. 6 But lack of target specific action and probability of host cell toxicity are the major limitations of these synthetic drugs. 10, 11 Taking into consideration, the severity of the infection and imperative necessity for a novel multidirectional, target specific and, non-toxic nature; the tunable nanotechnology based approaches seems to be a promising alternative. This technology harbors certain fascinating properties such as superparamagnetism, high surface plasmon resonance, luminescence, photon upconversion, bioavailability, biocompatibility, immunocompatibility / tolerability and biodegradability. The capacity to channelize through translucently breachable blood-brain barrier (BBB) and blood-air barrier (BAB), tunability and targeted control discharge are chief exclusive points which qualify them to be novel candidate for their utilization in biomedical therapy (antiviral). 1, 12 The focal point of present review paper includes cellular molecular pathogenesis of NiV infection. Heterogeneous forms of nano-based approaches used as a means of therapy or diagnostic against other viruses, and finally, provised the future possibilities for nanotechnology in concern with the NiV detection and inhibition. In humans, severe acute respiratory sickness and/ or encephalitis can be provoked by a bat-borne zoonotic, paramyxoviral pathogen NiV. 13, 14 This negative-sense single-stranded RNA virus belongs to the family Paramyxoviridae, genus Henipavirus and is closely related to Hendra viruses. 13, 15 Like Hendra virus, NiV may also cause fatal pneumonia or an acute respiratory-distress-like syndrome. 13, 16 It has been hypothesized that the respiratory disease transmission and pathogenesis are linked to infection of epithelial cells by the NiV at lower respiratory tract at the primary phase. 17 Recently Escaffre et al have described two types of infection in association to NiV, namely NiV-M and NiV-B of human respiratory tract based on differentiated epithelial models of trachea and small airways due to their close anatomical resemblance with epithelial cells of human lower respiratory tract. 13 According to the epidemiological reports NiV-M and NiV-B infections vary greatly in multiple aspects. 18 For instance the percentage of respiratory disease and case fatality rate of NiV-B infections is much higher than NiV-M infection, 19 whereas in NiV-M infection studies show that both human and hamster develop similar pathological changes such as presence of vasculitis, necrosis and inflammation. And certain neuronal changes such as antigen positive neurons, microvascular vasculitis and necrosis in hamster which in case of human progresses to encephalitis. 18, 20 An extracellular pleomorphic bilayer envelope spiked with two glycoproteins namely trimeric fusion protein (F) and tetrameric attachment protein (G) at the exterior surface and matrix proteins (M) at the interior surface, encapsulates NiV virion. 16, 21, 22 Further, the negative-sense single-stranded RNA, along with three other critically vital proteins namely nucleo-capsid proteins (N), phosphoproteins (P) and large polymerase proteins (L) is contained within the virion made up of linear ribonucleoprotein (RNP). 21 Binding of viral G to the conserved receptors ephrin-B2 and ephrin-B3 marks the beginning of host cell and viral membrane fusion mediated by prior complex formation of viral G and F protein. 22 From an evolutionary point of view it could be assumed that, during initial epidemic period of NiV, it has developed a specific mechanism to evade innate immune action of Pterous bat. The evolutionary conservation of this particular immune mechanism within all mammals has made NiV a broad spectrum virus against them. 23, 24 The virus blocks the elicitation of innate and adaptive immune response by inhibiting synthesis of cytokines, interferon type I (IFN α/β). 25 The IFN α/β in case of viral infection, activate pathways within the viral infected cell which degrades viral mRNA and inhibits viral protein synthesis, hence hindering the rate of viral replication inside the infected cell and subsequently lowering viral load. 26, 27 Song et al describe that IFN α/β can act as both autocrine and paracrine signaling molecule, where IFN α and IFN β are producers. 28 Therefore it could be said that inhibition of IFN α/β synthesis may severely affect both autocrine and paracrine activity, which may further lead to impaired immune response (Barth et al 2016) . 29 The cellular and molecular changes during and post NiV infection starting right from NiV attachment and invasive pathogenesis leading to multiple organ failure have been explained in the Figures 1, 2 , and 3. Understanding these changes will significantly improve present knowledge essential for developing and evaluating therapeutics against NiV. NiV infection in the primary stage is restricted within the epithelial cells of host's upper and lower respiratory tract. 17 And NiV-F and G necessary for its fusion with the bipolar epithelial cell are at the epical side during initial infection period. 30 Here, G protein induced virus-cell fusion begins with the interaction between tetrameric G-protein head region and Ephrin B2/B3 on the epithelial cell. Simultaneously C-terminus region of G interacts with NiV-F protein, whose two hydrophobic N-terminal alpha helical heptad repeat domains (HR-1, HR-2) form a sixhelical bundle structure that transverses through cell membrane of the host initiating pH independent class I type membrane fusion ( Figure 2 ). [31] [32] [33] After the viral entrance through apical region, it replicates within the cell, sorting of proteins such as F and G on infected cell surface, is further destined for infection could also be regarded as markers. 32, 33 Unlike G, precursor form of F protein, F 0 get lodged within the membrane and activated through endocytosis followed by cathepsin L mediated endosomal degradation to form mature F 1/2 (Cifuentes-Muñoz et al 2017). 34 The local infection starts with the lateral spreading of virus occurred by basolaterally expressed protein (G, F) mediated cellcell merging that gives rise to a consequential configuration of syncytia which are pathological hallmarks for NiV infection of epithelial cells. This has been seen at 14 h of post infection (p.i) which is the earliest time needed for protein detection in in vivo study. 30 The cell-cell fusion can be between epithelial cell and stromal cell, heterologous fusion or between two epithelial cells, homologous fusion ( Figure 2 ). 35 After disrupting monolayer epithelial cells the newly formed virus buds out from the apical side of the multinucleated epithelial cells. This vectorial release of virus is confirmed by the preferential localization of viral F, G and necessary for budding, M protein on the apical side (88%, 86%, 95% of total G, F and M respectively), which can be seen after 24 h p.i. 30 The released virus can either infect the immune cells of secondary lymphoid organs (Mucosal Associated Lymphoid Tissues [MALT], Gut Associated Lymphoid Tissues [GALT]) which are present just under the layer of mucosal epithelia cells. They might also contribute towards impairing antiviral activity by inhibiting synthesis of IFN α/β and reducing expression of cytokines involved in inflammatory process like CCL4, CCL5 and TNF-α. Again IFN induced antiviral genes such as MxA, ISG54 and repression of viral antigen presenting class-I MHC molecules might be another output (Figure 3, D) . 36, 37 The unconstrained virus could infiltrate the blood stream attaching to leukocytes such as macrophages, dendritic cells, CD6 + CD8 + T cells, NK cells causing systemic infection and multiple organ failure in detailed brain, lungs, liver, heart, kidney and spleen (( Figure 1) . 38 Histopathological lesions are necrosis and vasculitis in non-CNS organs. In case of CNS organs, perivascular cuffing, parenchymal inflammation and neurophangia are most common clinical signs, but are not exclusive for NiV infection and may also be detected in other acute viral encephalitis ( Figure 1 ). 36, 39 With mortality rate of 40%-75% and an outrageous range of host, this atrocious human pathogen also infects neurons apart from endothelial cells. 40 In general, paramyxoviruses evade host immune system either by suppressing its detection through lowering the expression of pattern recognition receptors (PRRS) or by impeding the secretion of antiviral signaling molecules. 37 In case of NiV, viral P gene encoded post-transcriptionally modified phosphoproteins antagonize the secretion of IFN α/β and elicit antiviral activity at both cytoplasm and nucleolus. 37, 41 The various proteins encoded by P genes are P, V, W and C with 407 amino acid length similarity at their N terminal end. 41 V and W mRNAs are frame shift mutates P mRNA at a particular conservation site, with insertion of one and two G nucleotide respectively whereas the C mRNA is nested within each P, V, W mRNA. 37, 42 The degree of immune response inhibition by each proteins P, V, W varies with P being less than V and W with highest inhibitory activity. 37, 43 The elevated inhibition by W protein might be because of its nuclear localization ability. 41, 47 This allows it to suppress expression of IFN α/β and antiviral gene at gene expression level and confirms lower probability of eliciting antiviral activity, than as happens in case of cytoplasmic inhibition by V proteins. 37, 44, 45 The cytoplasmic inhibitory activity of V proteins is achieved by its binding with dsRNA responding RLR receptor MAD5 hence down regulating the activation of TBK1 and IKKε which activates IFN α/β gene transcription factor IRF3 and IRF7 (Figure 3 , D.1). This suppression of IFN β gene expression can be overcome by another TLR3 mediated alternative pathway by producing more amount of adaptor protein IRF1 which activates TBK1 (Figure 3 , B.1). 37 Further, attenuation of IFNs responded antiviral activity of an infected cell can be discussed considering the JACK/STAT signaling pathway necessary for transcriptional level activation of antiviral genes. 37, 46, 47 Responding to IFN α/β and γ, the interactions between phosphorylated STAT1 and STAT2 form their hetero or homodimer (by STAT1 only) respectively (Figure 3 , D.2). These dimmers are precursor molecule of IFN α/β gene transcription factor. 48, 49 Hence inhibitions of STAT1 and STAT2 interaction result in the absence of antiviral activity. Protein P, V and W interact with STAT1 with their amino terminal domain while only protein V can interact with STAT2. 37 Re-localization of non-phosphorylated STAT1 from its typically cytoplasmic location by protein W also makes its unavailability for STAT dimer formation and hence inhibition of IFN α/β gene transcription factor formation ( Figure 3, D. 3). 37 The viral C protein which is predominantly localized in cytoplasm and partly in nucleus is responsible for enveloped viral budding and release by recruiting host ESCRT pathway. 50, 51 The C terminal domain of NiV-C, as it possesses homology in its sequence with host protein Vps28 could interact directly with TSG 101, an adaptor molecule between ESCRT I and ESCRT II. However, the reciprocal action among ESCRT I-NiV C and ESCRT II is not fully understood. 50 But it has been speculated that viral C protein interacts with M protein present in the inner leaflet of plasma membrane and thereby direct vectorial release of virus particles (Figure 3 , B.2). 50, 52 Therapeutics against NiV Guillaume et al developed a potent Vaccinia virus (VV) mediated VV-NiV-F and VV-NiV-G recombinant vaccines in a hamster model. 53 They found immunized organism shows complete immunity against NiV induced fatal encephalitis by producing neutralizing antibodies whereas it occurs within 7 to 10 days after intraperitoneal inoculation of NiV isolates. The low neutralizing ability of the produced antibodies as confirmed by the increasing level of serum antibodies gives an idea of studying effect of passive immunization against NiV. Intraperitoneal injection of polyclonal as well as monoclonal (mAb) anti-F and anti-G, separately shows that anti-F and anti-G mAb are more efficient in neutralizing NiV viral infection as compared to polyclonal Ab, with anti-F mAb having high degree of antiviral activity than anti-G mAb. 54 A recent hit on broad-spectrum small molecule antiviral purine analogue previously mentioned Favipiravir (T-705) which inhibits NIV and HeV replication in vitro with a minimal cytotoxic effect of highest concentration tested, having a CC 50 value of N1000 μl (as observed in Hamster model) has provided a way to fight against the cytopathic effect of deadly NiV, HeV like paramyxoviruses. 6 It is not late when one day due to the consistent change in their genome these pathogens would get resistance to the conventional drugs which are unidirectional and have no specific targeted. These limitations could be ameliorated by finding a novel therapy with multiple pathways and biomarkers for the target oriented action. For example in NiV depletion of NiV-C recruited ESCRT pathway mechanism and deposition of other viral proteins (N, M, F, G and L) results in cytoplasmic budding and impaired release of virus from the infected cell. 50 The versatile mode of viral inhibition primarily depends on the type and form of NPs used. Therefore to understand the antiviral activity of NPs a general overview about different types and forms of NPs/ nano-based systems is a necessity. Nano-based antiviral agents extend from simple inorganic NPs to complex organic and hybrid nanosystems. Metallic NPs (MNPs) and NCs in the form of nanospheres, nanocapsule and nanocage could be categorized under inorganic NPs (INPs). Organic NPs (ONPs) include nanocapsule as in the form of NCs, primarily differentiated based on chemical composition. Hybrid nanosystems are stan-dardized amalgamation of inorganic-organic, inorganic-inorganic (nanocomposites), and organic-organic nanoparticulated systems (lipid-polymer hybrid NPs) engineered based on specific requirement or use at targeted site. 55 The other properties such as luminescence, tunable size, shape, composition and large surface-to volume ratio have invigorated the importance of INPs in biomedical field for multifarious application. Among these applications the ability of these INPs to expose their multiple surface binding sites as well as control their in vivo behavioral properties is widely explored. 12 This phenomenon of multiple interactions at a specific site with the targeted molecule further contributes towards the utilization of these NPs in active targeted imaging for diagnostics, hyperthermia therapy and medication. 56 The most common iNPs are MNPs such as silver (Ag), gold (Au), iron oxide (FeO) and NCs of silica, titanium, carbon etc. Silver nanoparticles (AgNPs) are most keenly researched nanobased approach to treat viral infection or their detection. Numerous evaluations of the NPs to develop a novel strategy to either annihilate or ameliorate the severity of infection had already been carried out. To date the efficiency of AgNPs as an antiviral has been checked in Human immunodeficiency virus (HIV)-1, Herpes simplex virus (HSV)-1, 2, 3, Feline Calicivirus, Poliovirus type-1, Peste des petits ruminants virus (PPRV), Murine norovirus-1, Avian 57 Normally gp120 interaction with host receptor CD4 and associated coreceptor results in further conformational changes in virus, exposing gp41 which concordantly interacts and releases viral core into cytoplasm. 58 Their findings suggested that AgNPs impedes CD4-dependent virion binding, merging and pathogenesis by interacting with viral gp120 in both cell-free and cell-associated virus. 58 In case of HSV-2 the viral inhibition is portrayed by interacting with sulfhydryl group present on the membrane glycoproteins which prevent viral internalization. In Peste des petits ruminants' virus the NPs act by interacting with virion surface and core protein, impairing viral replication and entry. 59, 60 Likewise in dsRNA viruses the AgNPs after interaction with viral genome, the NPs were found to inhibit viral replication. 61 The antiviral efficacies of AgNPs by these modes of viral entry or attachment inhibition or viral replication inhibition have also been evaluated in other viruses shown in Table 1 . Unlike AgNPs though AuNPs could also be synthesized by green synthesis method but their direct use as an antiviral agent is scant. Except in some findings, that too when, AuNPs stabilized with certain biocompatible polymer could act as an effective antiviral agent against HIV-1, H1N1, H3N2, H5N1, dengue virus, bovine viral diarrhea virus and Foot-and-mouth disease virus (FMDB). 62-64 Vijayakumar and Ganesan et al had speculated that the mode of antiviral activity of polyethylene glycol encapsulated AuNPs against HIV-1, might be by blocking gp120 attachment with CD4, which results in inhibited viral entry. 62 Hafashjani et al in their finding later suggested that AuNPs arrested FMDV replication at post-entry stage, associated specifically with transcription within the host cell. 63 But the exact virucidal mechanism is unclear. The currently used AuNPs in combination with other nano-based formulation are applied for photothermal nanotherapy, bio-sensing, bio-imaging, catalytic activities. 65 The unique property of AuNPs contributing to these applications is different from its bulk form that is, Surface Enhanced Raman Scattering (SERS). 66 Iron oxide or superparamagnetic iron oxide in the form of either magnetite (Fe 3 O 4 ) or maghemite (Fe 2 O 3 , γ-Fe 2 O 3 ) NPs is the most imperative component of present day magneto responsive nanoparticulated systems. 67 These iron based nanoparticulated systems have created a tremendous impact in biomedical/ clinical diagnostics including magnetic resonance imaging, magnetic particle imaging, magnetic fluid hyperthermia and magnetic labeling and cell separation. 68 Therefore the direct application of MNPs as a therapeutic is limited. Presently the direct use of MNP as an antiviral agent has been evaluated against Bacteriophages such as MS2 and other highly infectious viruses like zika virus, HCV, H5N2 (Table 1) . [69] [70] [71] [72] There have been many other findings of exploiting MNPs but their application in hybridized form is much more appreciated, which is described later under Hybrid nanoparticles (Table 3) . Due to its brightness and high refractive index, titanium dioxide (TiO 2 ) a white pigmented molecule is widely used for a number of purposes. In various sectors of science and industries its nanoform that is TiO 2 NPs is more abundantly produced and used specifically because of their high solubility, photocatalytic and anticorrosive properties. 73 Although their application in biomedical sector is marvels but still than their there is a large gap between classic and current research. Out of every possible implementation that could bridge this gap, antiviral application of TiO 2 NPs is one of them. Present antiviral evaluation of TiNPs is only limited to influenza virus (H3N2) and certain bacteriophages such as MS2, PRD1, ɸX174, Fr and many others. [74] [75] [76] Moreover, the existing toxicity evaluations of the NPs though cannot completely eliminate health risks therefore, their biomedical application as an antiviral agent is questionable. 77 But considering beneficial role of TiNPs in biomedical sector, its antiviral activity however, needs to be perfectly conceptualized in animal models too. NPs based on silica due to their unique characteristics like tunable diameter, pore size, convenience in functionalization, biocompatibilities etc. are well appreciated for research all over the globe. 78, 79 Apart from these, there are two other important properties, which display manipulative applicable properties including self-immobilization of ligands onto surface of SiNP and stimuli-responsive gatekeepers. 80 The practical application lies in their capability to control or accelerate release of the drug payloads simultaneously excluding premature release. Currently, exploiting these properties for photodynamic therapy by functionalizing SiNPs with photosensitizers, is one of the fastest emerging research. 79 There are different forms of SiNPs, categorized as porous, mesoporous and non-porous and are utilized for diverse biomedical application. 78, 81 Out of the multiple biomedical applications of SiNPs, the present review focuses on antiviral activity as the research in antiviral therapeutics or diagnostics, exploiting silica based NPs is limited. 82, 83 Currently antiviral efficacy of SiNPs against some viruses like Human Papilloma Virus, Porcine circovirus, Hepatitis B virus, HSV-1, 2, HIV and recombinant viruses has been evaluated ( Table 1) . And the mode of antiviral activity is either mediated by immunization of the host against virus or by inhibiting viral entry. 82, 84 Viral protein based fluorescent detection and nucleic acid hybridization are the two major methods of viral detection. 83, 85 Despite the progress made in the therapeutics and diagnostics against viral infections, an achievement that cannot be questioned, the growing demand for a novel antiviral therapeutics or diagnostics can only be supplemented by further research and evaluations. Carbon-based nanocarriers are among the most frequently and widely evaluated nanoparticulated systems in biomedical application. The carbon-based materials such as fullerenes, carbon nanotubes, nanohorons, nanodots, grapheme and nanodiamonds etc. that also possess some of the above mentioned inimitable properties such as optical, electronic, mechanical and thermal properties have gained themselves much attention in the past decade. Among various beneficiary roles, biocompatibility, in vivo biodistribution, biodegradation and bio-corona formation etc. are few crucial properties that constantly impress the present scientific community till today. 86 Although carbon-based nanomaterials are supported by these spectacular advantageous properties, but still their utilization and evaluation in the field of virology are limited to some viruses (Table 1) . Antiviral or virucidal activities of these carbon-based nanomaterials have been evaluated against some viruses such as Ebola virus (pseudotyped viral particles), Bacteriophage λ, HIV-1, H3N2, Grass carp reovirus (GCRV) and Respiratory syncytial virus (RSV). [87] [88] [89] [90] [91] Various modes of viral inhibition by carbon-based nanomaterials used as carriers are represented in Table 1 . Advancement in the evaluation of carbonbased nanosystems against viral infection, though have developed immensely, but their commercialization is a rate-limiting phase and will be resolved with respect to time. 86, 92 The nano-sized semiconductor crystals commonly known as quantum dots (QDs) with their exceptional electronic and optical properties are highly appreciated. 93, 94 Specifically intensive fluorescence, high quantum yield, size-tunable light emission, appreciable chemical and photo-stability have revolutionized the concept of nano-based sensing or diagnostics. General elemental composition of QDs includes cadmium (Cd), lead (Pb), mercury (Hg) and zinc (Zn). But recently developed ternary I-III-VI QDs contain elements in different form, here "I" represents cupper (Cu) or silver (Ag), "III" represents gadolinium (Ga) or indium (In) and "VI" represents sulfur (S) or selenium (Se). 94 Owing to their extremely small size ranging from 2 to 10 nm QDs are well appreciated and used in biomedical sector as they could conveniently cross the BBB in conjugation with a therapeutic molecule. 94, 95 Mahajan et al showed that fluorescent quantum rods (QRs) a form of QD in conjugation with transferring, a targeting molecule and HAAT (Highly Active Antiretroviral Therapy) drug Sequinavir could freely cross an in vitro model of BBB. They also showed that the nano-formulation showed promising antiviral activity against HIV-1. 96 Viral detection by QD based approaches is exceedingly escalating research of virology. Norouzi et al developed a cadmium-tellurium QD in association with a biotin acceptor and NH 2 -receptor probes with target DNA for recognition of human T-lymphotropic virus-1 (HTLV-1) in vitro. 97 Likewise, there are many other evaluations where QDs have been utilized either as therapeutics or for in vitro diagnosis of viral pathogens. If the size of therapeutic compound is very large, then INPs might not prove promising in carrying or delivering the desired compound. In those conditions Organic nanoparticles (ONPs) might prove beneficial in order to efficient carry or deliver the drug load. 98 Further the use of ONPs over INPs is well appreciated in biomedical sector specifically due to various safety issues. 99 Encapsulation of drugs favors avoiding off-target toxicity which results in enhanced augmentation at targeted site. Again, the mode of delivery of therapeutics could be modulated by selecting specific design features and chemical requirements for the synthesis purpose. Since, sustained release kinetics can directly influence therapeutic competence and toxicity of the nanosystem. 98 Multiple forms of ONPs are exploited in field of nanomedicine but only certain specific ONPs are presently being evaluated for their antiviral activity. These include polymeric NPs, lipid based NPs, dendrimers, neosomes and nanomicelles ( Table 2) . The exploitation of polymeric NPs for progress in the effectual antiviral treatment has been going on for more than a decade. Various forms of polymers (synthetic and natural) have immensely contributed towards meticulous understanding of definite properties such as biodistribution/ bioavailability, biocompatibility, immunocompatibility etc. in biomedical sector. But their uses either for development or for improvement of an antiviral have been investigated only for some pathogenic viruses like influenza, HIV and rabies virus ( Table 2) . [100] [101] [102] Their efficient self-assembly properties, nanosize, shape, and ability to be functionalized based on requirement to either carry the desired therapeutic agent in its core or conjugate the target molecule on its surface are simply magnificent. Recently, Joshy et al have demonstrated that amine functionalized polymeric gelatin NPs loaded with zidovudine against HIV. Simultaneously, they have also conducted hemolysis and aggregation studies to gain deeper understanding of other compatible properties of NPs. From their research they summarized that drug conjugated NPs showed promising biocompatibility and antiviral activity. 103 Deng et al on the other hand took a different approach by developing a universal influenza vaccine with double-layered protein NPs composed of tetramaric Matrix protein 2 (M2e) at its core and headless Hemagglutinin (HA) coating at its surface. The protein vaccine could induce substantial and prolonged immunity with complete protection of BALB/c mice against verity influenza A virus challenges. 104 With the contemporary improvement made in nanoscience it is certain that these impeccable polymeric NPs in near future will be soon used for the development of a novel antiviral against divergent array of infectious viruses like NiV. Currently developed solid-lipid NPs and nanostructured lipid nanocarriers have demonstrated their ability as an exceptional efficient biocompatible vehicle for therapeutics in the field of advanced medicine. Among the multiple possible applications of lipid based NPs, their exploitation to formulate a novel antiviral could be assumed primary concern of ongoing researches. Further their anomalous bio-absorbable and biocompatible properties have granted these nanosystems a unique prospective to be viewed at. 105 Despite past limitations, where it seemed difficult for a therapeutic to migrate across BBB, it seems promising now with the introduction of multifunctional lipid based nanocarriers. In a 208 R.G. Kerry et al / Nanomedicine: Nanotechnology, Biology, and Medicine 18 (2019) 196-220 106 Similarly, Gao et al designed a nanostructured nanolipid carrier loaded with podophyllotoxin (POD) evaluated drug release parameters hemocompatibility and non-toxic viral inhibition in VK2/E6E7 cell lines challenged with Human papillomavirus (HPV). 107 Lipid based NPs in both of its form that is solid-lipid NPs and nanostructured lipid nanocarriers could serve as an exceptional addition to the group of vehicles needed for effective antiviral delivery. The current investigation of lipid-based NPs based antiviral against some viruses such as Hepatitis C virus, HIV and HPV has been documented ( Table 2 ). But certainly in future this marvelous nanosystem could get even better through hybridization, so that it could be used in efficiency of therapy against NiV. Dendrimer an organic compound with well-organized, hyperbranched molecule is receiving much attention lately owing to their improving monodispersity, biocompatibility and biodegradability in the field of nanomedicine. 108 This molecule is also an extraordinary vehicle for gene, peptide or drugs (natural/ synthetic) delivery at the targeted site within the biological system. 109 They are widely used in biomedical science, but their application and utilization for evaluating an antiviral are limited. To date, dendrimers with antiviral activity in conjugation with therapeutic agents have already been documented against some viruses including influenza virus, ebola virus, zika virus, HSV-1, 2 and HIV ( Table 2) . [111] [112] [113] The antiviral efficiency of nanosystems was a result of viral entry inhibition, activation of CD8 + T cell and/ or antibody mediated response and in some case RNA decoys. 111, 113, 114 Investigations regarding the efficacy of dendrimers as a nanoperticulated system for designing an antiviral therapy have been introduced by some of the pioneering researches, but their efficiency against NiV is yet to be evaluated. The non-ionic surfactant-based vesicle in short niosomes structurally similar to liposome is slowly becoming the center of attraction of current investigators. Its physical and chemical properties such as stability, optical activity, biocompatibility, biodegradability, non-immunogenicity, and convenience in functionalization have greatly influenced the scientific community. 115, 116 Additionally, efficiency to load both lipophilic and hydrophilic drug with superior bioavailability and guarded release at the intended site have granted niosome a unique prospective in the field of nanomedicine. 117 Despite their immense significance, the use of niosomes in biomedical sector specifically in formulation of antiviral agents is limited. For example till now antiviral activity against only HSV has been documented ( Table 2 ). Javad et al and Monavari et al have evaluated the efficacy of acyclovir loaded nano-niosome against HSV-1. They found that the neosomes loaded with the drug showed promising antiviral activity with improved delivery and release kinetics. 118, 119 Further in vivo evaluations are required to display the antiviral efficacy against other broad range of infectious viruses such as NiV. Nanomicelles are supramolecular assembly of a surfactant molecule disseminated in a colloidal liquid giving rise to a globular micelle ranging in nano-size. Efficient encapsulation, biocompatibility, colloidal stability and prolonged circulation time etc. are some of the influential properties of polymeric micelles. 120 Moreover, a compound possessing these properties is of huge significance in nanomedicine and drug delivery system (Table 2) . 121 Specifically to formulate an antiviral agent these polymeric nanomicelles is appreciated. For example Naseri et al formulated a nanomycelle encapsulating a bioactive phytocompound curcumin and verified bioavailability and antiviral activity in vitro. They documented that the nanoformulation displayed better bioavailability and satisfactory antiviral activity. 122 Present application of this marvelous compound is somewhat stagnant and needs more contribution from researchers all over the world. Hybrid NPs are by far the most advanced form of NPs that could be thought of in the present century. INPs such as Ag, Au, magnetic NPs, TiO 2 , SiO 2 , CNT, fullerene and graphene oxide and ONPs such as polymeric NPs, lipid NPs and niosomes have been explored in their antiviral activity. [123] [124] [125] There are a number of viruses against which these NPs in their hybridized state have been evaluated; these include HIV, influenza virus, hepatitis virus, human adenovirus etc. (Table 3) . Hybridized NPs in virology may be categorized according to their utilization that is either diagnostic or therapy. Current investigations, where efforts have been made towards diagnosis or detection of the viruses have been documented by many investigators from different corners of the globe. Starting from the primary application that is detection, Marjomäki et al earlier had reported an accurate and precise enteroviruses labeling procedure and described it at the atomic level. Here they reported water-soluble thiol-stabilized gold cluster or chemically called Au 102 (para-mercaptobenzoic acid) 44 cluster which by its metal core could covalently bind to cysteine molecule nearer to the surface of the virus. Through the above procedure enteroviruses echovirus 1 and coxsackievirus B3 viruses were precisely detected. 126 Ahmed et al have synthesized a multifunctional nanohybrid where AuNPs are first bonded with CNT surface, and then specific antibody (anti-influenza A virus HA H1 antibody) is conjugated to it. The nanohybrid displayed oxidative catalysis of 3, 3′, 5, 5′-tetramethyl-benzidine (TMB) by H 2 O 2 gave rise to a deep blue color, the optical density of which depended on concentration of virus. 127 Lately, Oh et al developed an ultrasensitive magnetic nanozyme-linked immunosorbent assay for detection of H1N1 virus. The assay had two major components, the silica-shelled magnetic nanobeads (MagNBs) for binding and preliminary detection of the virus, and a gold nanozyme (AuNZ) an enzymelike acting molecule for amplification of the preliminary detection signals. Together in combination the nanosystem could even detect virus concentration up to femtogram per milliliter. 128 There are a number of examples where hybridized nano-based systems showed promising results in viral detection; some of them have been listed in Table 3 . Viral inhibition is foremost important after diagnosis which needs to be addressed immediately; thereafter the requirement of a novel antiviral to combat the viral infectivity has become the primary concern. Further, development of an antiviral within a stipulated time is actually a race against time. Under such case formulation of an antiviral that is biocompatible, nonimmunogenic and non-toxic is of the critical requirement to which hybridized nanoparticulated systems are an appreciable option. It is because of the promising antiviral activity of these systems that has been portrayed by various scientific investigators. Ryoo et al had reported iron-oxide NP-based delivery of DNAzyme as a therapeutic for treating hepatitis C infection. Here, the magnetic NPs were linked to a cell-penetrating peptide (CPP) and functional DNAzyme which could induce knockdown of HVC gene NS3 (non-structural protein 3) encoding viral helicase and protease. 129 Orlowski et al developed tannic acid functionalized AgNPs of specific size range that could reduce HSV-2 infectivity by blocking viral attachment, penetration as well as viral spread; provided a prior direct attachment of the nano-system with the virus is a basic requirement. 130 Chen et al compared the antiviral activity of both graphene oxide (GO) and GO conjugated AdNPs against both coronavirus (FCoV) and infectious bursal disease virus (IBDV). Their analyses showed GO in its non-conjugated and conjugated form had different effect on two different taken viruses. Overall they concluded that GO in its conjugated form that is GO-AgNPs could inhibit both the virus that is FCoV and IBDV effectively. 131 After diagnosis and therapy the next arising huddle is drug resistance that soon must be focused and acted accordingly. With this intention Li et al, after much evaluations and strategic understanding the drawbacks of conventional and nano-based antiviral, designed nanoparticulated system by decorating amantadine (AM) on surface of selenium NPs (SeNPs). Their designed Se-AM nanosystem could reverse the drug resistance induced by H1N1 virus. 132 Similarly, there are many other investigations which orchestrate the experimental efficiencies of hybrid nanoparticulated systems as antivirals listed in Table 3 . Despite the heterogeneous research and investigations exploiting multiple ways and means to diagnose, inhibit the virus by a nano-based therapeutic agent or reverse the drug resistance, still there is hardly any sign of these applications concerning NiV. The elevated cost and in some case toxicity of conventionally available specific antiviral therapeutics have created an apparent requirement for specific and rapid viral diagnosis. Specific viral diagnosis may be helpful in discontinuation of broad spectrum antibiotic therapy and determination of prognosis, and it is also believed that rapid test result greatly influences case management. Prior to therapy, diagnosis therefore may be considered as an important aspect in viral infection treatment. There are multiple methods in the present era for laboratory based diagnosis of viral infection; these include serology, viral culture, antigen and nucleic acid detection. The conventional technique of viral detection that is viral culture may be considered as the only technique through which viable isolate could be obtained for future characterization. Additionally, detection of a diverse array of viruses seems promising with this approach, which is also an advantage over antigen detection and nucleic acid detection. In order to preserve medically relevant viruses, maintenance of heterogeneous types of cultured cell is required as a support, which is a major limitation of this technique. Viral recovery through cell culture becomes difficult when the viral growth is slow; antigen detection in such cases is much useful. Rapidity and non-requirement of viral viability render immense plasticity in management and shifting of the specimens, which together may be considered as the major advantages of the technique. Fluorescent Antibody (FA) staining, Immunoperoxidase staining and Enzyme Immunoassay (EIA) etc. are crucial techniques involved in these methods. But viruses with antigenic heterogeneity and lack of cross-reacting antigens are tedious to be detected even through this technique. Drastic transformation in diagnosis has emerged with the development of analysis based on PCR. This transformation has allowed the detection of specific viral sequence with uttermost sensitivity. More specifically, viral RNA could be easily detected only by amalgamating reverse transcriptase with conventional PCR analysis. Real-Time PCR assay runs on highly sophisticated automated instruments; exploiting optical excitation systems and dyes labeled with fluorescent molecules has tremendously reduced time and probable contamination. The versatility of nucleic acid detection is growing day-by-day and will be in future with the progression of scientific innovation. Finally, the efficacy serology the traditional method viral diagnosis cannot be disregarded. The technique is exclusively promising for unambiguous antiviral immunity determination, but when speculated on clinical utility, assessment of acute and convalescent antibody titers, could be one of its limitations. 133 In case of NiV detection these mentioned detection techniques may be fruitful. Upon considering the present encroachment in the field of nanoscience and virology, their intermediated research has initiated a new direction in rapid diagnosis of infectious viruses. Like Au/CuS core/shell NPs developed by Broglie et al for human norovirus-like particle detection and inactivation by capsid protein degradation and damage, 124 similarly a hybrid nanosystem could also be designed for binding with NiV virion two spiked glycoproteins F and G as well as RNA, and capsid proteins such as N, P, L contained within the virion (Figure 4) . 21 A colorimetric viral detection assay exploiting peroxidase-like activity of AuNPs-CNT nanohybrid could also be developed for detection of NiV detection like Ahmed et al, who synthesized and examined the same nanohybrid for the detection of H3N2. 127 Likewise there are a number of versatile experimentation (Tables 1, 2, and 3) where diagnoses of a verity of viral infections have been summarized. Contemplating on these possibilities, the probabilities of developing a novel nanobased diagnosis technique for detecting NiV could be achieved. If NiV detection could be possible, then elimination of the virus through nano-based system is not far or out of reach from the present investigators. The conventional means of viral inhibition or treatment / therapy have been documented under the topic "Therapeutics against NiV". The nano-based approaches like the use of acid functionalized multi-walled carbon nanotube (MWCTs) made of photoactivated molecules (Protoporphyrin IX) to inactivate H3N2 virus have been demonstrated by Banerjee et al. 87 The possible molecular mechanism involved is ROS-based inactivation through which oxidation of viral protein (neuraminidase [NA] and hemagglutinin [HA]) might have taken place; single stranded break in viral genome and protein-RNA crosslinking might have also been a possibility. Similar nano-based approach including pH or photothermal medium accompanied with ROSbased inactivation of NiV could also be evaluated in vitro. Inhibition of viral binding with the host cell surface receptor could also be achieved by preventing viral binding of gp120 and CD4 attachment. In a study, Vijayakumar and Ganesan have demon-strated this mode of inhibition of HIV-1 virus entry using AuNPs in vitro. 62 Similarly, NPs with the capacity to interact with NiV surface glycoproteins like G and F could prove to be promising candidates as viral entry inhibitors. Inhibition of virus mediated accumulation of ROS, activation of AKT, and p53 phosphorylation could also be a strategy for inhibiting the entry of infectious viruses. Li et al demonstrated this strategy of H1N1 viral inhibition using oseltamivir (OTV) decorated SeNPs (Se@OTV). 134 This strategy could be effectively evaluated in vitro in case of NiV inhibition. Likewise modulation of viral transcription using MWCTs-ribavirin by Zhu et al, 135 targeted binding on conservative regions on viral genome using TiO 2 NPs and polylysine (PL)containing oligonucleotides nanocomposite by Levina et al. 136 and silencing viral replication with the help of solid lipid NPs by Torrecilla et al 137 etc. all point in the same direction (Tables 1, 2, and 3). Though the efficiency of NPs as an antiviral agent against NiV is yet to be evaluated; still it could be roughly speculated that these investigations are direct representation of the possibility that NPs holds an enormous potential as an antiviral agent against NiV described in Figure 4 . Nanotechnology holds a tremendous opportunity for both viral disease diagnosis and their therapeutics. It is evidenced that NPs could be used as a measure to revert the antiviral resistance which is a slowly developing problem of conventional therapeutic available. Though it is possible that nano-based approaches are the next convenient strategy to deal with NiV, but still developing NPs is difficult if the NiV pathogenesis is not properly understood. Therefore the present review provides a brief knowledge about NiV pathogenesis at cellular and molecular level, where it would be easy to strategize a novel antiviral target using NPs. A brief introduction of various NPs in inorganic, organic and hybrid forms would be helpful in determining their suitability to be evaluated as diagnostics or therapeutics. Finally the overview of major antiviral approaches that have already been studied is represented in tabular format, which could help to strategize possible novel antiviral approach. The role of nanotechnology in the treatment of viral infections Viral lower respiratory tract infection in infants and young children World Health Organization. Case fatality rate Listing of the top ten causes of death compiled by the WHO A treatment for and vaccine against the deadly Hendra and Nipah viruses T-705) protects against Nipah virus infection in the hamster model A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody Status of vaccine research and development of vaccines for Nipah virus Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase Coronavirus susceptibility to the antiviral remdesivir (GS5734) is mediated by the viral polymerase and the proofreading exoribonuclease Recent advances of biocompatible inorganic nanoparticles towards biomedical applications Characterization of Nipah virus infection in a model of human airway epithelial cells cultured at an air-liquid interface Nipah virus contamination of hospital surfaces during outbreaks Characteristics of Nipah virus and Hendra virus replication in different cell-lines and their suitability for anti-viral screening Nipah virus infection: current scenario A human lung xenograft mouse model of Nipah virus infection Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia in the Syrian Hamster The emergence of Nipah virus, a highly pathogenic paramyxovirus Nipah virus infects specific subsets of porcine peripheral blood mononuclear cells Structure of Nipah virus unassembled nucleoprotein in complex with its viral chaperone Nipah virus fusion protein: importance of the cytoplasmic tail for endosomal trafficking and bioactivity Origin and evolution of Nipah virus Molecular epidemiology and phylogeny of Nipah virus infection: a mini review Interferon production and signaling pathways are antagonized during Henipavirus infection of fruit bat cell lines Antiviral actions of interferons Alpha/Beta interferon inhibits cap-dependent translation of viral but not cellular mRNA by a PKR-independent mechanism Type I interferons function as autocrine and paracrine factors to induce autotaxin in response to TLR activation Microbial degradation of cellular kinases impairs innate immune signaling and paracrine TNFα responses Nipah virus entry and egress from polarized epithelial cells Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling Differential rates of protein folding and cellular trafficking for the Hendra virus F and G proteins: implications for F-G complex formation Unraveling a three-step spatiotemporal mechanism of triggering of receptor-induced Nipah virus fusion and cell entry Mutations in the transmembrane domain and cytoplasmic tail of Hendra virus fusion protein disrupt virus-like-particle assembly Characterization of the antigen processing machinery and endogenous peptide presentation of a bat MHC class I molecule Novel Nipah virus immune-antagonism strategy revealed by experimental and computational study Nipah and hendra virus interactions with the innate immune system Pathogenesis of Hendra and Nipah virus infection in humans Pathogenic differences between Nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively Distinct and overlapping roles of Nipah virus P gene products in modulating the human endothelial cell antiviral response Nuclear localization of the Nipah virus W protein allows for inhibition of both virus-and toll-like receptor 3-triggered signaling pathways The nonstructural proteins of Nipah virus play a key role in pathogenicity in experimentally infected animals Possible role of the Nipah virus V protein in the regulation of the interferon beta induction by interacting with UBX domain-containing protein1 Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway An Alternative STAT signaling pathway acts in viral immunity in Caenorhabditis elegans Interferon-stimulated genes and their antiviral effector functions Recent advances in antiviral interferon-stimulated gene biology Nipah virus C protein recruits Tsg101 to promote the efficient release of virus in an ESCRT-dependent pathway Region of Nipah virus C protein responsible for shuttling between the cytoplasm and nucleus Henipavirus infection: natural history and the virus-host interplay Specific detection of Nipah virus using real-time RT-PCR (TaqMan) Evidence of a potential receptor-binding site on the Nipah virus G protein (NiV-G): identification of globular head residues with a role in fusion promotion and their localization on an NiV-G structural model Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform Actively targeted deep tissue imaging and photothermal-chemo therapy of breast cancer by antibody-functionalized drug-loaded X-ray-responsive bismuth sulfide@mesoporous silica core-shell nanoparticles Mode of antiviral action of silver nanoparticles against HIV-1 HIV: cell binding and entry Inhibition effect of silver nanoparticles on herpes simplex virus 2 Silver nanoparticles impair Peste des petits ruminants virus replication Biological activity of green-synthesized silver nanoparticles depends on the applied natural extracts: a comprehensive study Gold nanoparticles as an HIV entry inhibitor Gold nanoparticles impair foot-and-mouth disease virus replication Detection of influenza virus using peroxidase-mimic of gold nanoparticles Photothermal nanotherapeutics and nanodiagnostics for selective killing of bacteria targeted with gold nanoparticles Simple size-controlled synthesis of Au nanoparticles and their size dependent catalytic activity Magnetic iron oxide nanoparticles: recent trends in design and synthesis of magnetoresponsive nanosystems Novel magnetic multicore nanoparticles designed for MPI 216 and other biomedical applications: from synthesis to first in vivo studies Rapid and specific influenza virus detection by functionalized magnetic nanoparticles and mass spectrometry Adsorption of bacteriophage MS2 to magnetic iron oxide nanoparticles in aqueous solutions Aptamer-conjugated magnetic nanoparticles for the efficient removal of HCV particles from human plasma samples Highly sensitive, engineered magnetic nanosensors to investigate the ambiguous activity of Zika virus and binding receptors Titanium dioxide nanoparticles: a review of current toxicological data Photocatalytic inactivation of viruses using titanium dioxide nanoparticles and lowpressure UV light Interaction of titanium dioxide nanoparticles with influenza virus Inactivation of MS2 bacteriophage by titanium dioxide nanoparticles in the presence of quartz sand with and without ambient light Critical review of the safety assessment of titanium dioxide additives in food Advances in multicompartment mesoporous silica micro/nanoparticles for theranostic applications Mesoporous silica nanoparticles for recent photodynamic therapy applications Recent advance on mesoporous silica nanoparticles-based controlled release system: intelligent switches open up new horizon Nonporous silica nanoparticles for nanomedicine application Viral inhibition mechanism mediated by surfacemodified silica nanoparticles Femtogram level sensitivity achieved by surface engineered silica nanoparticles in the early detection of HIV infection Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein Enhancing the sensitivity of DNA microarray using dye-doped silica nanoparticles: detection of human papilloma virus Biological interactions of carbon-based nanomaterials: from coronation to degradation Light-activated nanotubeporphyrin conjugates as effective antiviral agents Glycofullerenes inhibit viral infection Single-walled carbon nanotubes as candidate recombinant subunit vaccine carrier for immunization of grass carp against grass carp reovirus Antiviral activity of fullerene C60 nanocrystals modifiedwith derivatives of anionic antimicrobial peptide maximin H5 Synergistic antiviral effect of curcumin functionalized graphene oxide against respiratory syncytial virus infection Quantum dots for fluorescent biosensing and bio-imaging applications Quantum dots in imaging, drug delivery and sensor applications Theranostic quantum dots for crossing blood-brain barrier in vitro and providing therapy of HIVassociated encephalopathy Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles Quantum dot-based biosensor for the detection of human T-lymphotropic virus-1 Organic nanoparticles for drug delivery and imaging Is nano safe in foods? Establishing the factors impacting the gastrointestinal fate and toxicity of organic and inorganic food-grade nanoparticles Polymeric nanoparticles as delivery system for influenza virus glycoproteins Effect of functionalization of polymeric nanoparticles incorporated with whole attenuated rabies virus antigen on sustained release and efficacy In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine Gelatin modified lipid nanoparticles for anti-viral drug delivery Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery Poly (vinyl pyrrolidone)-lipid based hybrid nanoparticles for anti viral drug delivery Development of podophyllotoxin-loaded nanostructured lipid carriers for the treatment of condyloma acuminatum Mechanistic studies of viral entry: an overview of dendrimerbased microbicides as entry inhibitors against both HIV and HSV-2 overlapped infections PEGylated dendrimerentrapped gold nanoparticles with low immunogenicity for targeted gene delivery Inhibition of herpes simplex virus type 1 and type 2 infections by peptidederivatized dendrimers Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose Evaluation of G2 citric acid-based dendrimer as an adjuvant in veterinary rabies vaccine An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8 + T cell responses in a mouse model Potential inhibition of HIV-1 encapsidation by oligoribonucleotidedendrimer nanoparticle complexes Self-assembled surfactant nano-structures important in drug delivery: a review Niosomes (non ionic surfactant vesicles) preparation and stability in biological environment Nanotechnologyapplied curcumin for different diseases therapy Preparation and evaluation of the antiviral activity of acyclovir loaded nano-niosomes against herpes simplex virus type 1 Ataei-Pirkooh A. The inhibitory effect of acyclovir loaded nano-niosomes against herpes simplex virus type-1 in cell culture Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability The antiviral effects of curcumin nanomicelles on the attachment and entry of hepatitis C virus Simple route to enhanced photocatalytic activity of p25 titanium dioxide nanoparticles by silica addition Antiviral activity of gold/ copper sulfide core/shell nanoparticles against human norovirus virus-like particles A multi-functional gold/ironoxide nanoparticle-CNT hybrid nanomaterial as virus DNA sensing platform Site-specific targeting of enterovirus capsid by functionalized monodisperse gold nanoclusters Enhanced catalytic activity of gold nanoparticle-carbon nanotube hybrids for influenza virus detection Magnetic nanozyme-linked immunosorbent assay for ultrasensitive influenza a virus detection Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection Antiviral activity of graphene-silver nanocomposites against non-enveloped and enveloped viruses Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways Diagnostic virology Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus Carbon nanotube-based nanocarrier loaded with ribavirin against grass carp reovirus High antiviral effect of TiO2·PL-DNA nanocomposites targeted to conservative regions of (−) RNA and (+) RNA of influenza a virus in cell culture Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES) Plantderived nanoparticles enhance antiviral activity against Coxsackievirus B3 by acting on virus particles and Vero cells Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3 In vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza a virus Antiviral activity of silver nanoparticles immobilized onto textile fabrics synthesized by radiochemical process Cytotoxicity and antiviral activity of electrochemical -synthesized silver nanoparticles against poliovirus Antiviral properties of silver nanoparticles against norovirus surrogates and their efficacy in coated polyhydroxyalkanoates systems Antiviral activity effect of silver nanoparticles (AgNPs) solution against the growth of infectious bursal disease virus on embryonated chicken eggs with ELISA test The inactivation of phages MS2, ΦX174 and PR772 using UV and solar photocatalysis TiO2~DNA nanocomposites as efficient site-specific antiviral agents against influenza A virus in cell culture Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide A novel dengue virus detection method that couples DNAzyme and gold nanoparticle approaches Observations of immuno-gold conjugates on influenza viruses using waveguide-mode sensors Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus Colorimetric detection of influenza A virus using antibody-functionalized gold nanoparticles Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro Development of a new method based on unmodified gold nanoparticles and peptide nucleic acids for detecting bovine viral diarrhea virus-RNA Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza a viruses Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity Antiviral properties of silver nanoparticles on a magnetic hybrid colloid Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B Core virus-like particles GAG mimetic functionalised solid and mesoporous silica nanoparticles as viral entry inhibitors of herpes simplex type 1 and type 2 viruses Fullerene derivatives strongly inhibit HIV-1 replication by affecting virus maturation without impairing protease activity Synthesis of giant globular multivalentglyco fullerenes as potent inhibitors in a model of Ebola virus infection Antiviral activity of self-assembled glycodendro [60] fullerene mono adducts The protective immunityagainst grass carp reovirus in grass carp induced by a DNA vaccination using single-walled carbonnanotubes as delivery vehicles Protective immunity of grass carp immunized with DNA vaccine encoding the vp7 gene of grass carp reovirus using carbon nanotubes as a carrier molecule Photoinduced antiviral carbon nanohorns Antiviral activity of graphene oxide: how sharp edged structure and charge matter Progression of respiratory syncytial virus infection monitored by fluorescent quantum dot probes Carbon dots as inhibitors of virus by activation of type I interferon response Carbon Dots' antiviral functions against noroviruses Intranasal immunization against influenza virus using polymeric particles N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model Development of core-corona type polymeric nanoparticles as an anti-HIV-1 vaccine Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy Reactive oxygen species-regulating polymersome as an antiviral agent against influenza virus Novel dendritic structure of alginate hybrid nanoparticles for effective anti-viral drug delivery Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles Synthesis of silica-coated magnetic nanoparticles and application in the detection of path Self-assembled star-shaped chiroplasmonic gold nanoparticles for ultrasensitive chiro-immunosensor of viruses Size-controlled preparation of peroxidase-like graphene-gold nanoparticle hybrids for the visible detection of norovirus-like particles Detection and differentiation of influenza viruses with glycan-functionalized gold nanoparticles Targeting and enrichment of viral pathogen by cell membrane cloaked magnetic nanoparticles for enhanced detection Virus inactivation by silver doped titanium dioxide nanoparticles for drinking water treatment The antiviral effect of fullerene-liposome complex against influenza virus (H1N1) in vivo Synthesis and evaluation of antiviral activities of novel sonochemical silver nanorods against HIV and HSV viruses Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 influenza virus through ROS-mediated signaling pathways Delivery of VP1 siRNA to inhibit the EV71 virus using functionalized silver nanoparticles through ROS mediated signaling pathways Efaverinz and nano-gold-loaded mannosylated niosomes: a host cell-targeted topical HIV-1 prophylaxis via thermogel system Enhanced inhibition of influenza virus infection by peptide-noble metal nanoparticle conjugates Nanoparticles as antiviral agents against adenoviruses The immune response to Nipah virus infection The interferons and their receptorsdistribution and regulation Type 1 interferons and antiviral CD8 T-cell responses Authors are grateful to their respective universities for support.